Bladder Cancer


Bladder cancer is the fourth most common cancer in the US. Due to its easily accessible location and relatively early diagnosis, bladder cancer is one of the least lethal cancers and there are ~540,000 survivors in the US. At presentation, >80% of bladder tumors are organ-confined, separated clinically into two groups. The most common group is the nonmuscle-invading tumors, accounting for about 70-80% of cases. This group is managed by surgery, plus neo- or adjuvant intravesical immunotherapy or chemotherapy. Intravesical therapy involves instilling a drug solution into the bladder through an indwelling catheter. Recurrence is common and occurs in 40 to 80% of patients. Between 10 to 20% of recurrences are accompanied by grade and/or stage progression (including the more fatal metastatic disease). The second group, the muscle-invading tumors, is managed by partial or complete cystectomy (removal of bladder), which presents significant risks and is not well-tolerated by older patients. The most commonly used chemotherapeutic agents for intravescial therapy are mitomycin C (MMC) and doxorubicin. Through a series of preclinical and clinical studies, our group has established that the efficacy of these agents is limited by two factors: inadequate drug delivery to tumors and low chemosensitivity (especially for the more aggressive tumors).


Relevant Publications


Lu, Ze, Yeh, T.K., Tsai, M., Au, J.L.-S., and Wientjes, M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res., 10:7677-84, 2004.


Xin, Y., Lyness, G., Chen, D., Song, S., Wientjes, M.G., and Au, J.L. Low dose suramin as a chemosensitizer of bladder cancer to mmc. J. Urol., 174:322-7, 2005.


Au, J.L. and Wientjes, M.G. Combination intravesical hyperthermia and chemotherapy for bladder cancer. Oncology (Williston. Park), 24:1155-1160, 2010.


Lu, Z., Yeh, T.K., Wang, J., Chen, L., Lyness, G., Xin, Y., Wientjes, M.G., Bergdall, V., Couto, G., Alvarez-Berger, F., Kosarek, C.E., and Au, J.L-S. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J. Urol., 185:1478-1483, 2011.